LeMaitre Vascular(NASDAQ) LMAT

LeMaitre makes tools to fix damaged blood vessels and veins. These products help surgeons treat heart and kidney disease patients. The company builds medical devices used during complex vascular surgeries.

Tools for Vascular Health

• Biologics: Patches and grafts made from processed animal or human tissue; accounts for 53% of net sales in Q1 2026.
• Valvulotomes: Specialized cutting tools that prepare veins to function like arteries in the lower leg or foot.
• Catheters: Thin, flexible tubes used to remove blood clots or temporarily block flow during operations.
• Carotid Shunts: Temporary bypass tubes that maintain blood flow to the brain during neck surgery.
• Closure Systems: Titanium clips used to attach blood vessels to one another instead of using traditional stitches.

New Products and Regions

• Bought the AndraValvulotome product line from Andramed GmbH in December 2025 to expand surgical tool offerings.
• Obtained regulatory clearance to sell the Artegraft cow-tissue graft in Europe, Australia, and Canada during 2025.
• Began moving human tissue processing for the RestoreFlow business to the Burlington headquarters in February 2026.
• Ended distribution contracts with AngioPro GmbH and Elutia to begin selling directly to medical facilities.

Controlling the Sales Process

LeMaitre generates 96% of its sales through a direct sales force rather than using third-party distributors. This strategy allows the company to maintain closer relationships with surgeons and support higher product prices.

Key Figures from Q1

• Net sales reached $66.6 million in Q1 2026, up 11.2% year-over-year.
• Net income hit $15.7 million in Q1 2026, up 42.4% from Q1 2025.
• Gross margin rose to 72.7% in Q1 2026, up from 69.2% in Q1 2025.
• Free cash flow hit $12.3 million in Q1 2026, up 60.8% year-over-year.

Bottom Line

LeMaitre has transitioned from a broad supplier to a specialized producer of high-margin biologics and niche surgical tools. By managing its own global sales force and manufacturing, the company maintains direct control over its primary medical markets.